The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
about
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal TransitionMicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionThe Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition.Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinomamiR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinomaInvolvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.The relationship between platinum drug resistance and epithelial-mesenchymal transition.MicroRNAs in gynecological cancers: Small molecules with big implications.Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.The miR-200 family in ovarian cancer.MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53.Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer.The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.A micRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.The Oxygen Paradox, the French Paradox, and age-related diseases.
P2860
Q28071987-B3B02AD3-670C-49C1-9032-5DB376AB9F79Q30244282-7B638DD7-3796-4CFC-907B-3372FD632E6CQ33829740-04FF20AB-F1E5-4461-9E73-6FE57F63DD4BQ33838714-422FB4CF-26C8-4589-B402-20A411F08D4BQ36320168-5A04C203-0791-497E-BD11-8D7FCBA721A9Q36775043-563EC145-D73E-4B74-BF7E-AB7B12A17BCEQ36962950-04FE51FB-B6DB-4CFC-9476-DE94B9532360Q37215530-E829B10C-8154-40E5-AD09-268B9DC2ED7FQ38745220-3A770CF3-DD05-4AFC-9656-51FE44870DF8Q38812266-834F8F1D-0AC3-4F25-BF3B-230E24A97816Q39061847-839F71E5-BDC2-4528-999A-CB66EC06390BQ39333266-74832FB0-4C0A-49C5-8F3C-8D9DF32682CAQ42215256-20E11633-AE62-4DC9-947A-FE0CD1D2CDAFQ42317503-F053072D-A730-445B-BF77-808A3C33D157Q42371676-BB7B0059-CAE9-45E0-8B53-BD7B28D2555DQ42378507-4F22633D-F1AB-42A6-9A5F-1F3B8F26B98CQ46227416-C1ABA92B-3B4D-4DB9-A310-1A438B596DDDQ47769339-C079DB4D-1CE4-4A96-804A-A14FD47418EEQ50006155-FE618A47-92F7-46AE-9CAD-481CE57AF002Q55384244-399C198A-B734-499F-9E8D-AA24BD207914
P2860
The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@ast
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@en
type
label
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@ast
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@en
prefLabel
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@ast
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@en
P2093
P2860
P1433
P1476
The miR-200 family differentia ...... noma OVCAR-3 and MES-OV cells.
@en
P2093
Branimir I Sikic
E Brian Francisco
George E Duran
Yan C Wang
P2860
P304
P356
10.1016/J.MOLONC.2015.04.015
P577
2015-05-16T00:00:00Z